Prosecution Insights
Last updated: November 04, 2026

Berg LLC

Technology area: Biotechnology & Pharmaceuticals

5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready

Analysis

Berg LLC has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners and 5 distinct art units, indicating separate examiner and technical assignments throughout the profile.

HALVORSON, MARK is the busiest examiner, with 1 pending matter. Because the matters are distributed across examiners and art units, counsel should use matter-specific response strategies while maintaining portfolio-level consistency where claim themes overlap.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

5
Total Pending OAs
3
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (20%)
2
Medium (40%)
2
Easy (40%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (20%)
§112 only2 (40%)
Double-patenting + other2 (40%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HALVORSON, MARK 1 47.9% +20.7%
SOROUSH, LAYLA 1 40.4% +43.6%
PLAYER, ROBERT AUSTIN 1 12.5% +34.7%
RODRIGUEZ, RAYNA B 1 33.5% +19.2%
SULLIVAN, STEPHANIE LAUREN 1 56.4% +39.0%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17953075 SYSTEMS AND METHODS FOR PATIENT STRATIFICATION AND IDENTIFICATION OF POTENTIAL BIOMARKERS PLAYER, ROBERT AUSTIN —

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
17274405 METHODS OF TREATING CANCER BY INHIBITING UBIQUITIN CONJUGATING ENZYME E2 K (UBE2K) SULLIVAN, STEPHANIE LAUREN 71d overdue
17981038 PREVENTING OR MITIGATING CHEMOTHERAPY INDUCED ALOPECIA USING VITAMIN D SOROUSH, LAYLA 44d overdue
18653809 USE OF MARKERS INCLUDING FILAMIN A IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER HALVORSON, MARK —
17953075 SYSTEMS AND METHODS FOR PATIENT STRATIFICATION AND IDENTIFICATION OF POTENTIAL BIOMARKERS PLAYER, ROBERT AUSTIN —
17341027 PREVENTING OR MITIGATING CHEMOTHERAPY INDUCED ALOPECIA USING VITAMIN D RODRIGUEZ, RAYNA B —

Top Art Units

Art UnitApps
1646 1
1622 1
1672 1
1628 1
1635 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18653809 USE OF MARKERS INCLUDING FILAMIN A IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER HALVORSON, MARK 1646 §112Other Non-Final OA — Pending May 02, 2024
17981038 PREVENTING OR MITIGATING CHEMOTHERAPY INDUCED ALOPECIA USING VITAMIN D SOROUSH, LAYLA 1622 §103DP Final Rejection 44d overdue Pending Nov 04, 2022
17953075 SYSTEMS AND METHODS FOR PATIENT STRATIFICATION AND IDENTIFICATION OF POTENTIAL BIOMARKERS PLAYER, ROBERT AUSTIN 1672 §101§103§112DP Non-Final OA — Pending Sep 26, 2022
17341027 PREVENTING OR MITIGATING CHEMOTHERAPY INDUCED ALOPECIA USING VITAMIN D RODRIGUEZ, RAYNA B 1628 §103DP Non-Final OA — Pending Jun 07, 2021
17274405 METHODS OF TREATING CANCER BY INHIBITING UBIQUITIN CONJUGATING ENZYME E2 K (UBE2K) SULLIVAN, STEPHANIE LAUREN 1635 §112 Final Rejection 71d overdue Pending Mar 08, 2021

Managing Berg LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Berg LLC have?

Berg LLC has 5 pending office actions as of November 2026, spread across 5 art units and 5 examiners.

Which USPTO examiner handles the most Berg LLC applications?

Mark Halvorson has the most, with 1 of Berg LLC's pending office actions.

What technology area are Berg LLC's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month